Delving into the Latest Updates on Terbutaline Sulfate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Terbutaline, Terbutaline Sulfate Granules, Terbutaline Sulfate Nebuliser

+ [19]

Target

β2-adrenergic receptor

Mechanism

β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesRespiratory Diseases

Active Indication

Bronchial SpasmBronchitisAsthma+ [4]

Inactive Indication

Asthma, Exercise-InducedEosinophilia, FamilialHypoglycemia+ [1]

Originator Organization

Sanofi

Active Organization

AstraZeneca Pharmaceuticals Co. Ltd.AstraZeneca KK

ANI Pharmaceuticals, Inc.

Inactive Organization

AstraZeneca PLC

Vectura Group Ltd.

Sanofi-Aventis U.S. LLC

Drug Highest PhaseApproved

First Approval Date

JP (08 Aug 1973),

AsthmaAsthmatic bronchitisBronchiectasis+ [2]

Regulation-

Login to view timeline

Structure

Molecular FormulaC12H19NO3

InChIKeyXWTYSIMOBUGWOL-UHFFFAOYSA-N

CAS Registry23031-25-6

View All Structures (2)

The overall aim in Part 1 is to compare the pharmacokinetic (PK)/pharmacodynamics (PD) relationship in intravenous (IV) versus subcutaneous (SQ) terbutaline sulfate to identify the optimal IV dosing range for use in Part 2.
The overall aim in Part 2 is to evaluate the optimal IV dosing of terbutaline sulfate based on PD response and safety data.

Start Date07 Jul 2023

Sponsor / Collaborator

Duke University

[+2]

NCT05494307 / Not yet recruitingPhase 2IIT

A Multicenter Randomized Trial of Second Line Treatment for Corticosteroid-Resistant or Relapsed Immune Thrombocytopenia: Combined Terbutaline and Danazol Versus Danazol Monotherapy

A randomized, open-label, multicenter study to compare the efficacy and safety of terbutaline plus danazol compared to danazol monotherapy for the second-line treatment of adults with corticosteroid-resistant or relapsed primary immune thrombocytopenia (ITP).

Start Date01 Sep 2022

Sponsor / Collaborator

Peking University People's Hospital

100 Clinical Results associated with Terbutaline Sulfate

Login to view more data

100 Translational Medicine associated with Terbutaline Sulfate

Login to view more data

100 Patents (Medical) associated with Terbutaline Sulfate

Login to view more data

3,522

Literatures (Medical) associated with Terbutaline Sulfate

01 Oct 2024·Brain, behavior, & immunity - health

Prenatal broad-spectrum cannabidiol administration prevents an autism-like phenotype in male offspring from a maternal stress/terbutaline rat model.

Article

Author: Taylor, Jeremy A ; Holbrook, Evan M ; Lowry, Christopher A ; Elkinbard, Isabella S ; Barth, Daniel S ; Smith, Zachariah Z ; Reuter, Jon D ; Anderson, Michael E

Recently, the diagnosis of autism spectrum disorder (ASD) has increased from 1 in 150 to every 1 in 36 children in the United States, warranting a need for novel prevention and therapeutic strategies. Broad-spectrum cannabidiol oil, free from delta-9-tetrahydrocannabinol, the psychoactive component of cannabis, may be one such therapeutic. It has a high safety profile and is frequently used as a complementary and integrative intervention by persons experiencing symptoms of anxiety, stress, and inflammation. Using a neurodevelopmental rat model of ASD (based on neuroinflammation induced by stress and terbutaline exposure during pre- and postnatal development), we sought to prevent the development of ASD-like behaviors in male offspring by administering broad-spectrum cannabidiol oil to dams throughout pregnancy (10 mg/kg, i.p., daily, embryonic days 3-16). To assess an ASD-like phenotype in the offspring, we used three behavioral measures relevant to three core ASD symptoms: 1) social communication (time spent vocalizing when alone); 2) repetitive behavior (marbles buried during a marble burying test); and 3) social interaction (time spent interacting with a novel conspecific during the three-chamber social interaction test). Broad-spectrum cannabidiol oil given during pregnancy decreased scores for all three ASD-related behavioral responses, resulting in an overall significant prevention of the ASD-like phenotype. These findings highlight the potential of broad-spectrum cannabidiol oil as a complementary and integrative approach for prevention of stressor-induced sequelae relevant to development of an ASD-like phenotype.

01 Oct 2024·The Journal of Allergy and Clinical Immunology: In Practice

Clinical and Economic Burden of Severe Asthma With Low Blood Eosinophil Counts

Article

Author: Martin, Neil ; Zhang, Ruiqi ; Lipworth, Joe ; Pfeffer, Paul ; Busby, John ; Naveed, Shamsa ; Chaudhuri, Rekha ; Patel, Mitesh ; Brown, Thomas ; Heaney, Liam G ; Burhan, Hassan ; Gore, Robin ; Pantin, Thomas ; Jackson, David ; Patel, Pujan ; Menon, Shruti ; Rupani, Hitasha

BACKGROUNDType 2 low-severe asthma phenotype is often a result of corticosteroid-overtreated type 2 disease owing to persistent symptoms, often unrelated to asthma and unlikely to respond to high-dose corticosteroid treatment.OBJECTIVEThis study aimed to characterize patients with severe asthma with low eosinophil counts (<300 cells/μL) and describe their disease burden and treatment across health care settings in the United Kingdom.METHODSA retrospective cohort study of patients with severe asthma using linked Clinical Practice Research Datalink (CPRD) Aurum-Hospital Episode Statistics (HES) and UK Severe Asthma Registry (UKSAR) data indexed patients according to the latest blood eosinophil count (BEC). Clinical characteristics, treatment patterns, outcomes, and health care resource use were described by baseline BEC (≤150 and >150 to <300 cells/μL).RESULTSAnalysis included 701 (CPRD-HES) and 1,546 (UKSAR) patients; 60.5% and 59.4% had BECs 150 cells/μL or less at baseline, respectively. Across BEC groups, the proportion with uncontrolled asthma (two or more exacerbations) at follow-up (12 months after the index) was 5.4% in CPRD-HES and 45.2% in UKSAR. Maintenance oral corticosteroid use remained high across BEC groups (CPRD-HES: 29.4%; UKSAR: 51.7%), symptom control remained poor (>200 μg short-acting β₂ agonist or >500 μg terbutaline/d in CPRD-HES: 48.8%; median Asthma Control Questionnaire-6 score in UKSAR: 2.0 [range, 1.0-3.3]). Health care resource use was similar across BEC groups.CONCLUSIONSMost patients managed in primary care experienced infrequent exacerbations, whereas UKSAR patients had frequent exacerbations. Large proportions of both patient groups had poor symptom control and continued to receive high levels of maintenance oral corticosteroids, increasing the risk of corticosteroid-induced morbidity. These data highlight the need for rigorous assessment of underlying disease pathology to guide appropriate treatment.

01 Oct 2024·Annals of the American Thoracic Society

Practice Patterns for Acute Asthma Exacerbation in Adult Patients Admitted to U.S. Intensive Care Units

Article

Author: Bosch, Nicholas A. ; Dobie, Aaron C. ; Homer-Bouthiette, Collin ; Pang, Brandon ; Shen, Burton H. ; Law, Anica C. ; Shankar, Divya A.

Rationale: Guidelines recommend systemic corticosteroids and inhaled β-agonists for patients with severe asthma exacerbation who are admitted to intensive care units. The benefits and utilization of adjunct treatments after guideline-recommended first-line treatments have been initiated are unclear. Objectives: Examine practice patterns of adjunct interventions in US intensive care units (ICUs) and their associations with outcomes for adults with severe asthma exacerbations. Methods: Using the multicenter PINC AI Healthcare Database of Premier Inc. (2016-2022), we sought to explore the use of adjunct interventions (medications [e.g., magnesium, leukotriene inhibitors, terbutaline, heliox] and procedures [e.g., invasive and noninvasive mechanical ventilation]) for adult patients admitted to U.S. ICUs with acute asthma exacerbations. We used hierarchical generalized linear models to calculate risk-adjusted rates of adjunct interventions and quantified between-hospital variation in adjunct interventions using the intraclass correlation coefficient (ICC; higher values correspond to higher between-hospital variation). We then used K-means clustering to identify groups of hospitals with similar risk-adjusted practice profiles of all adjunct treatments and examined associations between identified hospital clusters and patient outcomes. Results: We identified 62,392 patients from 961 hospitals for inclusion. Adjunct interventions with the highest between-hospital variation after risk adjustment were heliox (ICC, 91%), inhaled steroids (ICC, 23%), invasive mechanical ventilation (ICC, 21%), terbutaline (ICC, 22%), paralytics (ICC, 16%), and noninvasive ventilation (ICC, 15%). K-means clustering identified two distinct hospital clusters: Patients who were admitted to Cluster 1 hospitals (399 hospitals) had higher risk-adjusted rates of noninvasive ventilation (51% vs. 33%), compared with patients who were admitted to Cluster 2 hospitals (234 hospitals), which had higher risk-adjusted rates of invasive mechanical ventilation (63% vs. 30%). Cluster 2 was associated with fewer hospital-free days (β = -0.75 d; 95% confidence interval [CI] = -0.95, -0.55) and increased in-hospital mortality (adjusted odds ratio, 1.28; 95% CI = 1.17, 1.40). Conclusions: The use of adjunct interventions for patients with severe asthma exacerbations vary widely across U.S. hospitals; however, hospitals generally fall into two clusters differentiated primarily by the use of invasive or noninvasive mechanical ventilation. The cluster favoring noninvasive mechanical ventilation was associated with improved outcomes. Our results help to inform usual-care arms of future comparative effectiveness studies and efforts to standardize asthma practice.

100 Deals associated with Terbutaline Sulfate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00688	Terbutaline Sulfate	R03AC03 R03CC03	DB00871

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bronchial Spasm	CN	AstraZeneca Pharmaceuticals Co. Ltd.	01 Jan 1985
Bronchitis	CN	AstraZeneca Pharmaceuticals Co. Ltd.	01 Jan 1985
Asthma	JP	AstraZeneca KK	08 Aug 1973
Asthmatic bronchitis	JP	AstraZeneca KK	08 Aug 1973
Bronchiectasis	JP	AstraZeneca KK	08 Aug 1973
Bronchitis, Chronic	JP	AstraZeneca KK	08 Aug 1973
Pulmonary Emphysema	JP	AstraZeneca KK	08 Aug 1973

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Asthma	Preclinical	US	Sanofi-Aventis U.S. LLC	25 Mar 1974
Eosinophilia, Familial	Discovery	SE	AstraZeneca PLC	01 May 2005
Eosinophilia, Familial	Discovery	ES	AstraZeneca PLC	01 May 2005
Eosinophilia, Familial	Discovery	FR	AstraZeneca PLC	01 May 2005
Eosinophilia, Familial	Discovery	DE	AstraZeneca PLC	01 May 2005
Eosinophilia, Familial	Discovery	DK	AstraZeneca PLC	01 May 2005
Eosinophilia, Familial	Discovery	GB	AstraZeneca PLC	01 May 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03106753 (CTgov)	Phase 4	-	34	Terbutaline+Bupivacaine (Spinal Anesthesia Immediately for ECV.)	ewsimjjtsq(jvgxjbqgdw) = toslyiikzl twogecahym (rbekccbogz, qousdetwna - pnkmunetta) View more	-	09 Oct 2020
				Terbutaline+Bupivacaine (Spinal Anesthesia if no Intervention Fails for ECV.)	ewsimjjtsq(jvgxjbqgdw) = ccsfelywpz twogecahym (rbekccbogz, utzjqghzps - jfemrgrkur) View more
NCT02224157 (SYGMA2 \| SYGMA 2, CTgov)	Phase 3	Asthma	4,215	Placebo+Symbicort (Placebo Bid + Symbicort 'as Needed' (Experimental))	rndcplxemj(sxadymvoue) = oontmmjdbq ugegavpnmc (yezffbafmp, dmjsyhvhav - durpqzocly) View more	-	25 Nov 2019
				Terbutaline+Pulmicort (Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator))	rndcplxemj(sxadymvoue) = bovxvbpsge ugegavpnmc (yezffbafmp, wuvwszcaoo - ttbtngquyq) View more
NCT02149199 (SYGMA1 \| SYGMA 1, CTgov)	Phase 3	Asthma	3,850	Placebo+Symbicort (Placebo Bid + Symbicort 'as Needed')	touoxpwflf(lmegwxwlgi) = hotyqqyyzu dbbsgxmnpi (fagudmrpki, kiidpihpos - ifoyfkzmjs) View more	-	13 Sep 2019
				Placebo+Terbutaline (Placebo Bid + Terbutaline 'as Needed')	touoxpwflf(lmegwxwlgi) = ciseoinhnn dbbsgxmnpi (fagudmrpki, uuugigwwwj - dhpbcktsfw) View more
NCT02115256 (CTgov)	Phase 2/3	-	6	Intravenous Terbutaline (Intravenous Terbutaline)	sidhbvuxwq(frlyydoojh) = xieluhrjyh vhjukdvodl (mvyqajmats, tgphisbxws - zkdpguqscg) View more	-	14 Jun 2017
				Intravenous Nitroglycerine (Intravenous Nitroglycerine)	sidhbvuxwq(frlyydoojh) = ynaporhzai vhjukdvodl (mvyqajmats, avrorsipyr - dqcpgnrigf) View more
AAAAI2015	Not Applicable	-	-	Subcutaneous terbutaline	(bhbaqbfidt) = xzwscoegnx symungyuev (koecuzkobr )	Positive	01 Feb 2015
ERS2013	Not Applicable	-	10	Terbutaline	ppzslhucbf(meyjastojv) = jllcugkmws cpiryxropk (tjxvjqjzol ) View more	Positive	01 Sep 2013
				Placebo	ppzslhucbf(meyjastojv) = dhbqjthykd cpiryxropk (tjxvjqjzol ) View more
NCT00839800 (SAKURA, CTgov)	Phase 3	Asthma	2,091	Symbicort Turbuhaler (Symbicort SMART)	ehwldwgwxs(mqwvexhplo) = ttudsnhzcu cixfylcarq (lgwprxcgpy, lgxgjlwodu - cwfxpbvryu) View more	-	30 Nov 2012
				Terbutaline+Symbicort (Symbicort+Terbutaline As Needed)	ehwldwgwxs(mqwvexhplo) = rctexpezne cixfylcarq (lgwprxcgpy, cbonvcwczn - gsuzycxnzo) View more
NCT00989833 (MIA, CTgov)	Phase 2	Asthma, Exercise-Induced \| Intermittent asthma	66	Terbutaline+Budesonide (Budesonide/Terbutaline)	rdykykfjuu(ozkjtehzlj) = cdteexukay sxjtnpmcbd (jozaavguur, fprwtpzasj - czgwacbqgt) View more	-	14 Aug 2012
				Terbutaline (Terbutaline)	rdykykfjuu(ozkjtehzlj) = wpggpvuutg sxjtnpmcbd (jozaavguur, pgqhbxffln - paybkbuvgf) View more
NCT00567476 (CTgov)	Phase 4	Persistent asthma	116	Long-acting beta 2-adrenergic agonist (LABA)+terbutaline+salbutamol+Omalizumab (Omalizumab + Conventional Therapy)	qrccwsjyus(lqgfufvqww) = bapoofvdts kezjtkccrb (goqknvdhpp, oongldwdsc - rpkioorwti) View more	-	23 May 2011
				Long-acting beta 2-adrenergic agonist (LABA)+terbutaline+salbutamol (Conventional Therapy)	qrccwsjyus(lqgfufvqww) = dbwnowfjdx kezjtkccrb (goqknvdhpp, zjothvxqvp - tgizpevfbh) View more
AAAAI2004	Not Applicable	Asthma	697	Budesonide/formoterol	cojbpmayee(vbjjudddfh) = xwnuvjbyev baaazckceq (debqkoxcrv ) View more	Positive	01 Feb 2004
				Budesonide plus terbutaline	cojbpmayee(vbjjudddfh) = lcrvwlllfu baaazckceq (debqkoxcrv ) View more